Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
1.330
-0.050 (-3.62%)
At close: Mar 6, 2026, 4:00 PM EST
1.340
+0.010 (0.75%)
After-hours: Mar 6, 2026, 5:59 PM EST
Vivos Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Strong Buy
Price Target
$6.25
Upside
+369.92%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.5 → $5.5 | Strong Buy | Maintains | $6.5 → $5.5 | +313.53% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +426.32% | Nov 17, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.2 → $6.5 | Strong Buy | Maintains | $6.2 → $6.5 | +388.72% | Sep 9, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.6 → $6.2 | Strong Buy | Maintains | $6.6 → $6.2 | +366.17% | Apr 15, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Reiterates $6.6 | Strong Buy | Reiterates | $6.6 | +396.24% | Nov 20, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $8.25 → $6 | Strong Buy | Maintains | $8.25 → $6 | +351.13% | Nov 19, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.4 → $6.6 | Strong Buy | Maintains | $6.4 → $6.6 | +396.24% | Aug 20, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $63 | Strong Buy | Initiates | $63 | +4,599.25% | Jan 17, 2023 |
| Roth Capital | Roth Capital | Strong Buy Maintains $275 → $250 | Strong Buy | Maintains | $275 → $250 | +18,696.99% | Aug 13, 2021 |
| Roth Capital | Roth Capital | Strong Buy Maintains $300 → $275 | Strong Buy | Maintains | $300 → $275 | +20,576.69% | May 18, 2021 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $300 | Strong Buy | Initiates | $300 | +22,456.39% | Jan 11, 2021 |
| Roth Capital | Roth Capital | Strong Buy Initiates $300 | Strong Buy | Initiates | $300 | +22,456.39% | Jan 5, 2021 |